ToRaRI (Tofacitinib in Rheumatoid Arthritis a Real-Life experience in Italy): Effectiveness, safety profile of tofacitinib and concordance between patient-reported outcomes and physician's global assessment of disease activity in a retrospective study in Central-Italy

ConclusionsTofacitinib is safe and effective in our RA cohort. It induces higher remission rates in patients naive to bDMARDs, suggesting that there may be a benefit using it as first-line therapy. Additionally, improvement in PROs was consistent with PhGA scores, demonstrating how tofacitinib affects both the objective and subjective components of disease activity.Key Points1.JAK inhibitors are considered at a similar level as biologic agents in terms of effectiveness.2.After ORAL-Surveillance results, real-world data are needed to assess the benefit/risk profile of Jaki.3.Disagreement between patients and physicians has been previously reported with biologic therapy among patients with rheumatoid arthritis, with patients rating disease activity higher than physicians.4.Jak inhibitors could reduce this discrepancy, due to their mechanism of action.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research